MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ
1.495
-0.015
-0.99%
After Hours: 1.510 +0.015 +1.00% 19:38 12/08 EST
OPEN
1.510
PREV CLOSE
1.510
HIGH
1.519
LOW
1.490
VOLUME
10.20K
TURNOVER
0
52 WEEK HIGH
16.70
52 WEEK LOW
1.415
MARKET CAP
6.30M
P/E (TTM)
-1.0694
1D
5D
1M
3M
1Y
5Y
BRIEF-Qualigen Therapeutics Announces Pre-IND Feedback From U.S. Food And Drug Administration Regarding QN-302 For The Treatment Of G4-Targeted Advanced Solid Tumors
Reuters · 1d ago
Qualigen Therapeutics Announces Pre-IND Feedback From U.S. FDA Regarding QN-302 For The Treatment Of G4-Targeted Advanced Solid Tumors
Benzinga · 1d ago
QLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor…
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Preclinical Data on QN-302 Presented at AACR Conference on Pancreatic Cancer In September 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced the presentation of two p...
Zacks Small Cap Research · 12/01 12:11
Qualigen Therapeutics Announces 1-For-10 Reverse Stock Split
Benzinga · 11/22 14:01
Qualigen Therapeutics Launches 1-for-10 Reverse Stock Split
Qualigen Therapeutics Launches 1-for-10 Reverse Stock Split
MT Newswires · 11/22 09:46
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/18 21:32
BRIEF-Qualigen Therapeutics Reports Q3 Financial Results And Provides Corporate Update
Reuters · 11/15 12:42
Qualigen Therapeutics GAAP EPS of -$0.10 beats by $0.06, revenue of $1.44M misses by $0.18M
Seekingalpha · 11/15 12:42
More
About QLGN
Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer. The Company's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.

Webull offers kinds of Qualigen Therapeutics Inc stock information, including NASDAQ:QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.